Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

British Prime Minister Boris Johnson and Prime Minister Justin Trudeau elbow bump prior to a bilateral meeting during the G7 summit in Cornwall, Britain, June 11, 2021.

POOL/Reuters

Canada has pledged to provide up to 100 million doses of COVID-19 vaccine as part of a commitment by G7 leaders to supply more than one billion doses to the rest of the world over the next year.

Prime Minister Justin Trudeau is set to make the announcement on Sunday at the end of the G7 leaders’ summit in Cornwall, England.

“The pressure was on everyone to make sure that we are saying clearly to the world that these seven most wealthy countries will lead the way in making sure vaccines are available as widely as possible,” said Ralph Goodale, Canada’s High Commissioner to the U.K. “Canada’s global number is up to 100 million. And we recognize that with all of the countries doing their share, that’s still not enough … More will be required and more will be forthcoming.”

Story continues below advertisement

Canada won’t be donating any doses from its current supply, and Mr. Goodale told reporters on Friday that the pledge will not impact the domestic vaccination program this summer. Instead, Canada’s share of the one-billion-dose commitment has been calculated partly on the basis of financial support Ottawa has already provided to COVAX, an alliance co-led by the World Health Organization that is procuring vaccine for poorer countries. The federal government is also expected to forego future deliveries of doses the country no longer needs and redirect them to COVAX.

Prime Minister Justin Trudeau and other world leaders come together for the first time since the COVID-19 pandemic began on a beach in southwest England. British Prime Minister Boris Johnson greeted Trudeau before the leaders gathered with others, including U.S. President Joe Biden, for a photograph. The Canadian Press

The G7 — which includes Canada, the United States, Britain, France, Germany, Italy and Japan — has been under increasing pressure to do more to alleviate the growing gap in vaccinations between rich and less wealthy countries. While most G7 members are close to immunizing their adult populations, fewer than two per cent of people in Africa have received a single shot.

Britain and the U.S. have made the largest pledges so far. The U.S. plans to buy 500 million doses of the Pfizer-BioNTech vaccine, at not-for-profit prices, and donate most of it to COVAX, with the remainder going to selected countries over the next year. Britain will contribute 100 million doses to COVAX starting in September, by redirecting supplies that have been ordered but are now surplus.

Canada’s portion of the G7 commitment will come largely from the $545-million Ottawa has already pledged to COVAX, which will be used primarily to buy vaccines for low- and middle-income countries. Some of the money will also go toward vaccine distribution.

Canada is also expected to meet its share by rerouting future deliveries of vaccine, similar to what the U.K. plans to do. For example, Canada has ordered 52 million doses of the Novavax vaccine, which has yet to be approved by Health Canada. Those doses could instead be sent to COVAX, said a government source. The Globe is not identifying the source because they aren’t authorized to speak publicly.

Canada certainly has plenty of vaccine to share. Ottawa has ordered 252.9 million doses, enough to vaccinate every Canadian more than three times over. According to The Globe and Mail’s vaccine tracking, the government is on course to have enough supply to give two doses to all eligible Canadians by August.

While the G7 commitment has been welcomed by the WHO and some international development organizations, many groups said it falls far short of what’s needed. “If the best G7 leaders can manage is to donate one billion vaccine doses, then this summit will have been a failure,” said Anna Marriott, Oxfam’s health policy manager. She and others have pointed out that it will take 11 billion doses to vaccinate everyone.

Story continues below advertisement

Several organizations have also called on the G7 to waive patent protection rules for vaccines and commit to sharing technology in order to boost manufacturing. U.S. President Joe Biden and French President Emmanuel Macron have supported easing intellectual property rules, but Canada and other G7 countries have been less enthusiastic. They have argued that the bigger obstacles to vaccine production are export rules and the transfer of technology.

Some politicians in Africa have accused wealthy countries of imposing “vaccine apartheid” by blocking the waiver. “We asked for justice; they are giving us charity,” said Nanjala Nyabola, a Kenya-based political analyst and scholar, in a tweet.

During the summit, Mr. Trudeau held a bilateral meeting with British Prime Minister Boris Johnson. The two discussed vaccines and also raised the prospect of a Canada-U.K. trade agreement. Now that Britain has left the European Union, Britain is free to strike its own trade deals and Mr. Johnson has been eager to sign as many as possible.

According to Mr. Goodale, the two leaders felt that the current timetable for an agreement — roughly four years — was too long. “They both agreed we can do better than that,” he said. “They gave it a sense of urgency.”

With a report from Geoffrey York in Johannesburg


Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies